188 related articles for article (PubMed ID: 1701526)
1. Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age.
MacDonald ML; Wagner RM; Slotnick RN
Obstet Gynecol; 1991 Jan; 77(1):63-8. PubMed ID: 1701526
[TBL] [Abstract][Full Text] [Related]
2. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
[TBL] [Abstract][Full Text] [Related]
3. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study.
Phillips OP; Elias S; Shulman LP; Andersen RN; Morgan CD; Simpson JL
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):353-8. PubMed ID: 1379701
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
[TBL] [Abstract][Full Text] [Related]
5. Fetal gender impact on multiple-marker screening results.
Bazzett LB; Yaron Y; O'Brien JE; Critchfield G; Kramer RL; Ayoub M; Johnson MP; Evans MI
Am J Med Genet; 1998 Apr; 76(5):369-71. PubMed ID: 9556293
[TBL] [Abstract][Full Text] [Related]
6. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA
N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852
[TBL] [Abstract][Full Text] [Related]
7. Preliminary evidence for associations between second-trimester human chorionic gonadotropin and unconjugated oestriol levels with pregnancy outcome in Down syndrome pregnancies.
Benn PA
Prenat Diagn; 1998 Apr; 18(4):319-24. PubMed ID: 9602476
[TBL] [Abstract][Full Text] [Related]
8. Cigarette smoking and levels of maternal serum alpha-fetoprotein, unconjugated estriol, and hCG: impact on Down syndrome screening.
Palomaki GE; Knight GJ; Haddow JE; Canick JA; Wald NJ; Kennard A
Obstet Gynecol; 1993 May; 81(5 ( Pt 1)):675-8. PubMed ID: 7682315
[TBL] [Abstract][Full Text] [Related]
9. Unexplained elevated midtrimester maternal serum levels of alpha fetoprotein, human chorionic gonadotropin, or low unconjugated estriol: recurrence risk and association with adverse perinatal outcome.
Wax JR; Lopes AM; Benn PA; Lerer T; Steinfeld JD; Ingardia CJ
J Matern Fetal Med; 2000; 9(3):161-4. PubMed ID: 10914623
[TBL] [Abstract][Full Text] [Related]
10. Effect of gravidity on maternal serum markers for Down's syndrome.
Barkai G; Goldman B; Ries L; Chaki R; Cuckle H
Prenat Diagn; 1996 Apr; 16(4):319-22. PubMed ID: 8734805
[TBL] [Abstract][Full Text] [Related]
11. Serum markers for Down's syndrome in relation to number of previous births and maternal age.
Wald NJ; Watt HC
Prenat Diagn; 1996 Aug; 16(8):699-703. PubMed ID: 8878278
[TBL] [Abstract][Full Text] [Related]
12. Maternal serum superoxide dismutase (SOD): a possible marker for screening Down syndrome affected pregnancies.
Ognibene A; Ciuti R; Tozzi P; Messeri G
Prenat Diagn; 1999 Nov; 19(11):1058-60. PubMed ID: 10589060
[TBL] [Abstract][Full Text] [Related]
13. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
[TBL] [Abstract][Full Text] [Related]
14. Second-trimester maternal serum screening for Down syndrome in in vitro fertilization pregnancies.
Rice JD; McIntosh SF; Halstead AC
Prenat Diagn; 2005 Mar; 25(3):234-8. PubMed ID: 15791658
[TBL] [Abstract][Full Text] [Related]
15. Triploidy identified through second-trimester serum screening.
Huang T; Alberman E; Wald N; Summers AM
Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
[TBL] [Abstract][Full Text] [Related]
16. [Prenatal maternal blood screening for the detection of fetal chromosomal abnormalities: clinical importance of the rate of false positives].
Alvarez-Nava F; Soto M; Padrón T; Morales A; Villalobos D; Rojas de Atencio A; Prieto M; Martínez MC
Invest Clin; 2003 Sep; 44(3):195-207. PubMed ID: 14552058
[TBL] [Abstract][Full Text] [Related]
17. Combined ultrasound biometry, serum markers and age for Down syndrome risk estimation.
Bahado-Singh RO; Oz AU; Gomez K; Hunter D; Copel J; Baumgarten A; Mahoney MJ
Ultrasound Obstet Gynecol; 2000 Mar; 15(3):199-204. PubMed ID: 10846774
[TBL] [Abstract][Full Text] [Related]
18. Second trimester serum markers.
Canick JA; MacRae AR
Semin Perinatol; 2005 Aug; 29(4):203-8. PubMed ID: 16104669
[TBL] [Abstract][Full Text] [Related]
19. [Maternal serum alpha-fetoprotein as a screening test for fetal Down syndrome].
Bessho T; Kanazawa R; Shiotani T; Mitsuo M; Koyama K
Nihon Sanka Fujinka Gakkai Zasshi; 1995 Mar; 47(3):237-43. PubMed ID: 7535328
[TBL] [Abstract][Full Text] [Related]
20. Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markers.
Dugoff L; Cuckle HS; Hobbins JC; Malone FD; Belfort MA; Nyberg DA; Comstock CH; Saade GR; Eddleman KA; Dar P; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
Am J Obstet Gynecol; 2008 Sep; 199(3):290.e1-6. PubMed ID: 18771987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
